{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:56:06Z","timestamp":1793728566889,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    An unmet need exists for patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) and high-risk disease features, such as progression of disease within 24\u2009months (POD24) from first-line immunochemotherapy or disease refractory to both CD20-targeting agent and alkylator (double refractory), due to no established standard of care and poor outcomes. Chimeric antigen receptor (CAR) T cell therapy is an option in R\/R FL after two or more lines of prior systemic therapy, but there is no consensus on its optimal timing in the disease course of FL, and there are no data in second-line (2L) treatment of patients with high-risk features. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product. The phase 2 TRANSCEND FL study evaluated liso-cel in patients with R\/R FL, including 2L patients who all had POD24 from diagnosis after treatment with anti-CD20 antibody and alkylator \u22646\u2009months of FL diagnosis and\/or met modified Groupe d\u2019Etude des Lymphomes Folliculaires criteria. Primary\/key secondary endpoints were independent review committee\u2013assessed overall response rate (ORR)\/complete response (CR) rate. At data cutoff, 130 patients had received liso-cel (median follow-up, 18.9\u2009months). Primary\/key secondary endpoints were met. In third-line or later FL (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009101), ORR was 97% (95% confidence interval (CI): 91.6\u201299.4), and CR rate was 94% (95% CI: 87.5\u201297.8). In 2L FL (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923), ORR was 96% (95% CI: 78.1\u201299.9); all responders achieved CR. Cytokine release syndrome occurred in 58% of patients (grade \u22653, 1%); neurological events occurred in 15% of patients (grade \u22653, 2%). Liso-cel demonstrated efficacy and safety in patients with R\/R FL, including high-risk 2L FL. ClinicalTrials.gov identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04245839\">NCT04245839<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-024-02986-9","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T11:03:21Z","timestamp":1717412601000},"page":"2199-2207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":159,"title":["Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3714-9824","authenticated-orcid":false,"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-9156","authenticated-orcid":false,"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Martin Garcia-Sancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirit","family":"Ardeshna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Skarbnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Viardot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalia","family":"Farazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omotayo","family":"Fasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lymp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Vedal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Avilion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Papuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-6317","authenticated-orcid":false,"given":"Jinender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-8610","authenticated-orcid":false,"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"2986_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R. et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443\u2013459 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"2986_CR2","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.3324\/haematol.2016.148809","volume":"101","author":"AM Perry","year":"2016","unstructured":"Perry, A. M. et al. Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica 101, 1244\u20131250 (2016).","journal-title":"Haematologica"},{"key":"2986_CR3","doi-asserted-by":"publisher","first-page":"5843","DOI":"10.1002\/cam4.1805","volume":"7","author":"R Muto","year":"2018","unstructured":"Muto, R. et al. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 7, 5843\u20135858 (2018).","journal-title":"Cancer Med."},{"key":"2986_CR4","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.3390\/jcm12041417","volume":"12","author":"L-C Chiu","year":"2023","unstructured":"Chiu, L.-C. et al. Incidence trend of follicular lymphoma in Taiwan compared to Japan and Korea, 2001\u20132019. J. Clin. Med. 12, 1417 (2023).","journal-title":"J. Clin. Med."},{"key":"2986_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). B-Cell Lymphomas. Version 1.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf (National Comprehensive Cancer Network, 2024)."},{"key":"2986_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","volume":"32","author":"M Dreyling","year":"2021","unstructured":"Dreyling, M. et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32, 298\u2013308 (2021).","journal-title":"Ann. Oncol."},{"key":"2986_CR7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy, C. et al. Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J. Clin. Oncol. 37, 144\u2013152 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2986_CR8","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(22)00033-3","volume":"9","author":"C Casulo","year":"2022","unstructured":"Casulo, C. et al. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 9, e289\u2013e300 (2022).","journal-title":"Lancet Haematol."},{"key":"2986_CR9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo, C. et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J. Clin. Oncol. 33, 2516\u20132522 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2986_CR10","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3324\/haematol.2022.281421","volume":"108","author":"P Ghione","year":"2023","unstructured":"Ghione, P. et al. Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica 108, 822\u2013832 (2023).","journal-title":"Haematologica"},{"key":"2986_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"CA Jacobson","year":"2022","unstructured":"Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23, 91\u2013103 (2022).","journal-title":"Lancet Oncol."},{"key":"2986_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28, 325\u2013332 (2022).","journal-title":"Nat. Med."},{"key":"2986_CR13","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141, 1675\u20131684 (2023).","journal-title":"Blood"},{"key":"2986_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839\u2013852 (2020).","journal-title":"Lancet"},{"key":"2986_CR15","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"2986_CR16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23, 1066\u20131077 (2022).","journal-title":"Lancet Oncol."},{"key":"2986_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23, 1055\u20131065 (2022).","journal-title":"Lancet Oncol."},{"key":"2986_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1182\/blood-2023-173692","volume":"142","author":"SJ Schuster","year":"2023","unstructured":"Schuster, S. J. et al. Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study. Blood 142, 603 (2023).","journal-title":"Blood"},{"key":"2986_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu, S. S. et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143, 496\u2013506 (2024).","journal-title":"Blood"},{"key":"2986_CR20","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/blood-2022-158024","volume":"140","author":"M Dreyling","year":"2022","unstructured":"Dreyling, M. et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed\/refractory follicular lymphoma (r\/r FL) treated with tisagenlecleucel in the Elara trial. Blood 140, 1459\u20131463 (2022).","journal-title":"Blood"},{"key":"2986_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clml.2023.09.007","volume":"24","author":"F Bosch","year":"2024","unstructured":"Bosch, F. et al. Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed\/refractory follicular lymphoma. Clin. Lymphoma Myeloma Leuk. 24, 105\u2013121 (2024).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2986_CR22","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood-2023-178786","volume":"142","author":"LJ Nastoupil","year":"2023","unstructured":"Nastoupil, L. J. et al. Matching-adjusted indirect comparison (MAIC) of efficacy and safety of lisocabtagene maraleucel (liso-cel) and mosunetuzumab for the treatment (Tx) of third line or later (3L+) relapsed or refractory (R\/R) follicular lymphoma (FL). Blood 142, 2338 (2023).","journal-title":"Blood"},{"key":"2986_CR23","unstructured":"LUNSUMIO (mosunetuzumab-axgb). Prescribing information. Genentech, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761263s000lbl.pdf"},{"key":"2986_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"2986_CR25","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2986_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","volume":"127","author":"MS Cairo","year":"2004","unstructured":"Cairo, M. S. & Bishop, M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 127, 3\u201311 (2004).","journal-title":"Br. J. Haematol."},{"key":"2986_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","volume":"48","author":"K Cocks","year":"2012","unstructured":"Cocks, K. et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur. J. Cancer 48, 1713\u20131721 (2012).","journal-title":"Eur. J. Cancer"},{"key":"2986_CR28","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3109\/10428194.2012.762977","volume":"54","author":"FJ Hlubocky","year":"2013","unstructured":"Hlubocky, F. J. et al. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy \u2013 Lymphoma Symptom Index. Leuk. Lymphoma 54, 1942\u20131946 (2013).","journal-title":"Leuk. Lymphoma"}],"updated-by":[{"DOI":"10.1038\/s41591-024-03175-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02986-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02986-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T06:06:33Z","timestamp":1724047593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-02986-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2986"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-02986-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"12 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-03175-4","URL":"https:\/\/doi.org\/10.1038\/s41591-024-03175-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.M. discloses consultancy for AbbVie, Bristol-Myers Squibb, Genmab, Gilead, Novartis and Roche and service as an advisor for AbbVie, Gilead and Roche. S.D. discloses service as an advisor to Bristol-Myers Squibb and Kite\/Gilead and research funding from Kite\/Gilead. M.L.P. discloses honoraria from Cellectar Biosciences, Ceramedix, Juno Therapeutics, Garuda Therapeutics, Kite, Mustang Bio, Novartis, Pluto Immunotherapeutics, Rheos Medicines, Seres Therapeutics, Smart Immune, Synthekine and ThymoFox and royalties from Juno Therapeutics and Seres Therapeutics. A.M.G.-S. discloses consultancy for AbbVie, ADC Therapeutics America, Celgene, Clinigen, EUSA Pharma, Gilead\/Kite, Ideogen, Incyte, Kyowa Kirin, Eli Lilly, Miltenyi Biotec, Novartis, Roche and Takeda; honoraria from Celgene, EUSA Pharma, Gilead\/Kite, Janssen, Novartis, Roche and Takeda; travel from Celgene, Gilead\/Kite, Janssen and Roche; and service as an advisor for Bristol-Myers Squibb. J.L.R.O. discloses consultancy for Janssen and honoraria from Amgen, Bristol-Myers Squibb and Kite. J. Kuruvilla discloses consultancy for AbbVie, Bristol-Myers Squibb, Gilead, Merck, Roche and Seattle Genetics; honoraria from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Genmab, Gilead, Incyte, Janssen, Merck, Novartis, Pfizer, Roche and Seattle Genetics; service as an advisor for Karyopharm Therapeutics; and research funding from AstraZeneca, Merck and Roche. U.J. discloses honoraria from Bristol-Myers Squibb, Gilead, Janssen, Miltenyi Biotec, Novartis and Roche and research funding from Innovative Medicines Initiative 2 Joint Undertaking. G.C. discloses consultancy for AbbVie, Bristol-Myers Squibb, Emercell, MabQi, MedXCell, Onward Therapeutics and Roche and honoraria from AbbVie, Bristol-Myers Squibb, Gilead, Janssen, Novartis and Roche. K.I. discloses consultancy for AbbVie, AstraZeneca, Eisai, Genmab, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Otsuka, Nihon Shinyaku, Takeda and Zenyaku; honoraria from AbbVie, AstraZeneca, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Genmab, Janssen, Kyowa Kirin, Eli Lilly, Merck Sharp & Dohme, Nihon Kayaku, Novartis, Ono Pharmaceutical, Pfizer, SymBio Pharmaceuticals, Seika Pharma and Takeda; and research funding from AbbVie, Astellas, Amgen, AstraZeneca, BeiGene, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Genmab, Incyte, Kyowa Kirin, Loxo Oncology, Merck Sharp & Dohme, Novartis, Otsuka, Pfizer, Regeneron and Yakult. M.D. discloses honoraria from AstraZeneca, BeiGene, Gilead\/Kite, Janssen, Eli Lilly, Novartis and Roche; service as an advisor for AbbVie, AstraZeneca, BeiGene, Celgene, Gilead\/Kite, Janssen, Eli Lilly\/Loxo, Novartis and Roche; and research funding from AbbVie, Bayer, Celgene, Gilead\/Kite, Janssen and Roche. B.K. discloses honoraria from Bristol-Myers Squibb Germany and MSD Oncology and research funding from MSD Oncology and Takeda. H. Ghesquieres discloses consultancy for Gilead and Roche and honoraria from AbbVie, Bristol-Myers Squibb, Gilead and Roche. K.A. discloses travel from Bristol-Myers Squibb, Gilead and Novartis. H. Goto discloses honoraria from Bristol-Myers Squibb, Chugai, Novartis, AbbVie, Gilead\/Kite, Merck Sharp & Dohme, Daiichi Sankyo, Eisai, Kyowa Kirin and SymBio and research funding from Bristol-Myers Squibb, Kyowa Kirin, Sanofi and SymBio. A.M.B. and S.d.V. declare no competing interests. J.S.A. discloses consultancy for AbbVie, Alimera Sciences, AstraZeneca, BeiGene, bluebird bio, C4 Therapeutics, Caribou Biosciences, Celgene, Century Therapeutics, EMD Serono, Epizyme, Genentech, Genmab, Incyte, Janssen, Karyopharm Therapeutics, Kite\/Gilead, Kymera Therapeutics, Eli Lilly, MorphoSys, Mustang Bio, Novartis, Ono Pharmaceutical and Takeda; honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen and Regeneron; and research funding from AI Therapeutics, Bristol-Myers Squibb and Seattle Genetics. P.B. discloses honoraria from Bristol-Myers Squibb Germany and MSD Oncology and research funding from MSD Oncology and Takeda. I.F. discloses consultancy for AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb, Gilead, Incyte, Janssen, Novartis, Roche and Seagen and honoraria from Gilead, Incyte, Novartis and Seagen. S.M. discloses honoraria from Celgene, Novartis, Gilead\/Kite, Janssen, JAMP Pharma and Pfizer (via institution); service as part of a data safety monitoring board for Immunicum\/Mendes and Miltenyi Biotec (via institution); and founding leadership for SWECARNET (via institution) and founder for ScientifyResearch (spouse). A.S. discloses consultancy for Alexion Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Epizyme, Genentech, Genmab, Janssen, Kite, Eli Lilly, MorphoSys, Novartis, Pharmacyclics, Seagen and TG Therapeutics and honoraria from AbbVie, ADC Therapeutics, Alexion Pharmaceuticals, AstraZeneca, BeiGene, Epizyme, Genentech, Genmab, Janssen, Jazz Pharmaceuticals, Kite, MorphoSys, Pharmacyclics, Seagen and TG Therapeutics. M.K. discloses consultancy for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeiGene, Caribou Biosciences, Celgene, Genentech and Syncopation; service as an advisor for Celgene, Genentech and Seagen; and research funding from Novartis. R.K. discloses consultancy for AstraZeneca, BeiGene, Bristol-Myers Squibb, Calithera Biosciences, Epizyme, Genentech, Janssen, Kite\/Gilead, Eli Lilly Oncology, Miltenyi Biotec and MorphoSys; honoraria from AstraZeneca, BeiGene and MorphoSys; and other interests with Bristol-Myers Squibb, Calithera Biosciences, Kite\/Gilead and Miltenyi Biotec. A.V. discloses consultancy for AbbVie, Bristol-Myers Squibb, Kite\/Gilead and Roche; honoraria from AbbVie, Bristol-Myers Squibb, Kite\/Gilead and Roche; and research funding from Bristol-Myers Squibb. T.F., O.F., J.L., M.V., R.N., A.A., J.P. and J. Kumar are employees and equity holders of Bristol-Myers Squibb. L.J.N. discloses consultancy for Interius Biotherapeutics and SIRPant Immunotherapeutics; honoraria from ADC Therapeutics, Bristol-Myers Squibb, Caribou Biosciences, Epizyme, Genentech, Genmab, Gilead, Janssen Oncology, MorphoSys, Novartis, Roche, Takeda and TG Therapeutics; and travel from Genentech\/Roche.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}